文献速递白血病淋巴瘤

Tisagenlecleucel在复发难治性B-ALL和DLBCL中的免疫原性

Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma.
PubMed 文献 · Blood Adv · 2021-01-01

该研究 pooled 分析ELIANA、ENSIGN和JULIET试验,评估抗鼠CAR19抗体和T细胞反应对tisagenlecleucel疗效的影响。结果显示,尽管部分患者存在基线或治疗后抗体及T细胞反应,但均未影响CAR-T细胞的扩增、持续性、临床应答及安全性。

要点

  • 基线抗mCAR19抗体在B-ALL中占81%,DLBCL中占94%。
  • 治疗后抗体升高者B-ALL占42%,DLBCL占9%。
  • 抗体和T细胞反应均未影响tisagenlecleucel的疗效与安全性。

核心结论

  • 基线或治疗后抗mCAR19抗体及T细胞反应未改变tisagenlecleucel在r/r B-ALL或r/r DLBCL患者中的活性。

研究设计与样本

  • 数据来自ELIANA和ENSIGN试验的r/r B-ALL患者(N=143)及JULIET试验的r/r DLBCL患者(N=115),采用两种验证过的检测方法评估体液和细胞免疫反应。

主要发现

  • 治疗前抗mCAR19抗体在r/r B-ALL中检出率81%,在r/r DLBCL中94%。
  • 治疗后抗mCAR19抗体较患者特异性基线升高者,在r/r B-ALL中占42%,在r/r DLBCL中占9%。
  • 治疗前和治疗后抗mCAR19抗体不影响tisagenlecleucel的细胞动力学(包括最大浓度和持续性,r2<0.05)、临床应答(第28天应答、缓解持续时间和无事件生存)及安全性。
  • T细胞反应随时间保持一致,多数患者基线和治疗后时间点的净反应<1%,且对转基因扩增或持续性或结局无影响。

临床怎么用

  • 临床实践中,无需因基线或治疗后抗mCAR19抗体或T细胞反应的存在而改变tisagenlecleucel的使用决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tisagenlecleucel is indicated for pediatric and young adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) and adult patients with r/r diffuse large B-cell lymphoma (DLBCL). The tisagenlecleucel chimeric antigen receptor (CAR) contains a murine single-chain variable fragment domain; we examined the effects of humoral and cellular immune responses to tisagenlecleucel on clinical outcomes using 2 validated assays. Data were pooled from the ELIANA (registered at www.clinicaltrials.gov as #NCT02435849) and ENSIGN (#NCT02228096) trials in r/r B-ALL (N = 143) and the JULIET trial (#NCT02445248) in r/r DLBCL (N = 115). Humoral responses were determined by flow cytometric measurement of anti-murine CAR19 (mCAR19) antibodies in serum. Cellular responses were determined using T-cell production of interferon-γ in response to 2 different pools of mCAR19 peptides. Pretreatment anti-mCAR19 antibodies were detected in 81% of patients with r/r B-ALL and 94% of patients with r/r DLBCL. Posttreatment anti-mCAR19 antibodies were higher than patient-specific baseline in 42% of r/r B-ALL and 9% of r/r DLBCL patients. Pretreatment and posttreatment anti-mCAR19 antibodies did not affect tisagenlecleucel cellular kinetics, including maximum concentration and persistence (r2 < 0.05), clinical response (day-28 response, duration of response, and event-free survival), and safety. T-cell responses were consistent over time, with net responses <1% at baseline and posttreatment time points in a majority of patients and no effect on transgene expansion or persistence or outcomes. Presence of baseline and/or posttreatment anti-mCAR19 antibodies or T-cell responses did not alter the activity of tisagenlecleucel in patients with r/r B-ALL or r/r DLBCL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Thudium Mueller K, Grupp SA, Maude SL, et al. Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Blood Adv. 2021. PMID: 34432863. doi:10.1182/bloodadvances.2020003844

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。